Variations of Parathyroid Hormone and Bone Biomarkers Are Concordant Only After a Long Term Follow-up in Hemodialyzed Patients

Overview

Journal Sci Rep

Specialty Science

Date 2017 Oct 5

PMID 28974744

Citations 3

Authors

Pierre Delanaye

Xavier Warling

Martial Moonen

Nicole Smelten

Francois Jouret

Jean-Marie Krzesinski

Nicolas Maillard

Hans Pottel

Etienne Cavalier

Affiliations

Soon will be listed here.

Abstract

End-stage renal disease is associated with mineral and bone disorders. Guidelines recommending therapies should be based on serial assessments of biomarkers, and thus on variations (Δ), rather than scattered values. We analyzed the correlations between ΔPTH and Δbone biomarkers such as bone-specific alkaline phosphatase (b-ALP), Beta-CrossLaps (CTX), osteocalcin, intact serum procollagen type-1 N-propeptide (P1NP), and tartrate-resistant acid phosphatase 5B (TRAP-5B) at different time-points. In this prospective observational analysis, variations of biomarkers were followed after 6-week (n = 129), 6-month (n = 108) and one-year (n = 93) period. Associations between variations were studied by univariate linear regression. Patients followed for one-year period were classified (increaser or decliner) according to variations reaching the critical difference. Over the 6-week period, only ΔCTX was correlated with ΔPTH (r = 0.38, p < 0.0001). Over the one-year period, correlations between ΔPTH and Δbone biomarkers became significant (r from 0.23 to 0.47, p < 0.01), except with ΔTRAP-5b. Correlations between Δbone biomarkers were all significant after one-year period (r from 0.31 to 0.68, p < 0.01), except between Δb-ALP and ΔTRAP-5b. In the head-to-head classifications (decliners/increasers), the percentage of concordant patients was significantly higher over the one-year than the 6-week period. A concordance between ΔPTH and Δbone biomarkers is observed in dialysis patients, but only after a long follow-up.

Citing Articles

Osteocalcin and Abdominal Aortic Calcification in Hemodialysis Patients: An Observational Cross-Sectional Study.

Jia F, Wang S, Jing Y, Zhao H, Rong P, Zhang H Front Endocrinol (Lausanne). 2021; 12:620350.

PMID: 33815281 PMC: 8018234. DOI: 10.3389/fendo.2021.620350.

Bone turnover correlates with bone quantity but not bone microarchitecture in chronic hemodialysis.

Dusceac R, Niculescu D, Dobre R, Sorohan M, Caragheorgheopol A, Tacu C J Bone Miner Metab. 2020; 38(4):597-604.

PMID: 32144577 DOI: 10.1007/s00774-020-01094-1.

Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort.

Jean G, Lafage-Proust M, Souberbielle J, Lechevallier S, Deleaval P, Lorriaux C PLoS One. 2018; 13(6):e0199140.

PMID: 29912988 PMC: 6005469. DOI: 10.1371/journal.pone.0199140.

References

Vervloet M, Brandenburg V . Circulating markers of bone turnover. J Nephrol. 2017; 30(5):663-670. PMC: 5628199. DOI: 10.1007/s40620-017-0408-8. View

Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E . Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf). 2008; 69(2):189-96. DOI: 10.1111/j.1365-2265.2008.03187.x. View

Streja E, Wang H, Lau W, Molnar M, Kovesdy C, Kalantar-Zadeh K . Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone. 2014; 61:201-7. PMC: 4024455. DOI: 10.1016/j.bone.2014.01.016. View

Mundy G, Guise T . Hormonal control of calcium homeostasis. Clin Chem. 1999; 45(8 Pt 2):1347-52. View

Malluche H, Davenport D, Cantor T, Monier-Faugere M . Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol. 2014; 9(7):1254-62. PMC: 4078960. DOI: 10.2215/CJN.09470913. View

Reichel H, Roth H, Schmidt-Gayk H . Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clin Pract. 2005; 98(4):c112-8. DOI: 10.1159/000081552. View

Ketteler M, Block G, Evenepoel P, Fukagawa M, Herzog C, McCann L . Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017; 92(1):26-36. DOI: 10.1016/j.kint.2017.04.006. View

Garrett G, Sardiwal S, Lamb E, Goldsmith D . PTH--a particularly tricky hormone: why measure it at all in kidney patients?. Clin J Am Soc Nephrol. 2012; 8(2):299-312. DOI: 10.2215/CJN.09580911. View

Urena Torres P, Bover J, Mazzaferro S, De Vernejoul M, Cohen-Solal M . When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol. 2014; 34(6):612-25. DOI: 10.1016/j.semnephrol.2014.09.004. View

10.

Delanaye P, Dubois B, Jouret F, Krzesinski J, Moranne O, Cavalier E . Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so simple?. Clin Chim Acta. 2012; 417:35-8. DOI: 10.1016/j.cca.2012.12.009. View

11.

Cavalier E, Delanaye P, Moranne O . Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis. 2013; 61(5):847-8. DOI: 10.1053/j.ajkd.2012.12.013. View

12.

Cavalier E, Delanaye P, Collette J, Krzesinski J, Chapelle J . Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta. 2006; 371(1-2):107-11. DOI: 10.1016/j.cca.2006.02.029. View

13.

Jean G, Souberbielle J, Zaoui E, Lorriaux C, Mayor B, Hurot J . Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem. 2012; 45(6):436-9. DOI: 10.1016/j.clinbiochem.2012.01.018. View

14.

Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J, Bajo A, Mate A, Martinez E . Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant. 2004; 19(6):1587-93. DOI: 10.1093/ndt/gfh214. View

15.

Vasikaran S, Eastell R, Bruyere O, Foldes A, Garnero P, Griesmacher A . Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2010; 22(2):391-420. DOI: 10.1007/s00198-010-1501-1. View

16.

Moorthi R, Moe S . Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int. 2013; 84(5):886-94. PMC: 3805700. DOI: 10.1038/ki.2013.254. View

17.

Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y . Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int. 2008; 82(4):278-87. DOI: 10.1007/s00223-008-9127-4. View

18.

Reichel H, Esser A, Roth H, Schmidt-Gayk H . Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant. 2003; 18(4):759-68. DOI: 10.1093/ndt/gfg144. View

19.

Jean G, Chazot C, Charra B . 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol. 2007; 68(1):63-4. DOI: 10.5414/cnp68063. View

20.

Sprague S, Bellorin-Font E, Jorgetti V, Carvalho A, Malluche H, Ferreira A . Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2015; 67(4):559-66. DOI: 10.1053/j.ajkd.2015.06.023. View